Boehringer Ingelheim
VC Fund
Ingelheim Am Rhein, Germany
Boehringer Ingelheim is a research-driven group of companies dedicated to researching, developing, manufacturing, and marketing pharmaceuticals that improve health and quality of life. Our businesses comprise Prescription Medicine, Animal Health, and Biopharmaceuticals.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 40%
- Fund size:
- $250M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Boehringer Ingelheim invests in
Stages Boehringer Ingelheim invests in
Countries Boehringer Ingelheim invests in
Contacts
Investment Focus
Industry
- Health Care 5 (50%)
- Biotechnology 4 (40%)
- Medical 3 (30%)
- Therapeutics 3 (30%)
- Pharmaceutical 3 (30%)
Stage
- Grant 1 (10%)
- Series A 1 (10%)
- Series C 1 (10%)
- Series D 1 (10%)
- Funding Round 1 (10%)
Country
- United States 4 (40%)
- Kenya 1 (10%)
- Canada 1 (10%)
- Austria 1 (10%)
- Belgium 1 (10%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Anjan Chatterjee
Corporate Vice President
|
Corporate Vice President | Total investments: 0 | Find email | |
Christian Eckermann
SVP, Head of Biopharma Austria
|
SVP, Head of Biopharma Austria | Total investments: 0 | Find email | |
Ioannis Sapountzis
Global Head BD&L
|
Global Head BD&L | Total investments: 1 | Find email | |
Jan Cassen Kraus
Head of Supply Chain Management
|
Head of Supply Chain Management | Total investments: 0 | Find email | |
Klaus-Peter Kammerer
Global Clinical Program Leader
|
Global Clinical Program Leader | Total investments: 0 | Find email | |
| See all 8 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| THINKMD develops next-generation clinical assessment and data analytics platforms that transform point-of-care medicine by putting medically validated clinical assessment capability into the hands of non-healthcare professionals. This technology allows for the decentralization of healthcare delivery into communities and homes by pairing clinicalknowledge and Bayesian/pattern recognition algorithms with simple to use mobile technology. Its goal is to reinvent the healthcare delivery paradigm, reduce costs, and improve outcomes by improving healthcare access and care-seeking behavior while building a public health knowledge database. | Venture - Series Unknown / Aug 12, 2026 | ||
| Click Therapeutics develops and commercializes software as medical treatments for people with unmet medical needs. Through cognitive and neurobehavioral mechanisms, Click’s Digital Therapeutics™ enable change within individuals, and are designed to be used independently or in conjunction with biomedical treatments. The Clickometrics® adaptive datascience platform continuously personalizes user experience to optimize engagement and outcomes. Following a groundbreaking clinical trial, Click’s industry-leading smoking cessation program is available nationwide through a wide variety of payers, providers, and employers. Click’s lead prescription program is entering into a multi-center, randomized, controlled, parallel-group, phase III FDA registration trial for the treatment of Major Depressive Disorder in adults. | $50M / Series D / Apr 09, 2026 | ||
| Ilara Health brings accurate and affordable diagnostics to rural Africans through miniature, AI-powered diagnostic devices that are integrated via a proprietary technology platform and distributed directly to primary care doctors. | $1.7M / Debt Financing / Feb 12, 2024 | ||
| Yale Cancer Center is a cancer treatment center that provides prevention, detection, diagnosis, and treatment for cancer. They provide treatments for patient care,oncology, and hematology. | Mar 06, 2023 | ||
| Yale Cancer Center is a cancer treatment center that provides prevention, detection, diagnosis, and treatment for cancer. They provide treatments for patient care,oncology, and hematology. | Mar 05, 2023 | ||
| Click Therapeutics develops and commercializes software as medical treatments for people with unmet medical needs. Through cognitive and neurobehavioral mechanisms, Click’s Digital Therapeutics™ enable change within individuals, and are designed to be used independently or in conjunction with biomedical treatments. The Clickometrics® adaptive datascience platform continuously personalizes user experience to optimize engagement and outcomes. Following a groundbreaking clinical trial, Click’s industry-leading smoking cessation program is available nationwide through a wide variety of payers, providers, and employers. Click’s lead prescription program is entering into a multi-center, randomized, controlled, parallel-group, phase III FDA registration trial for the treatment of Major Depressive Disorder in adults. | $500M / Corporate Round / Sep 11, 2020 | ||
| Proxygen is reshaping the druggable space. Their company harnesses technology and know-how to exploit this potential, thereby redefining the borders of the druggable target space. They developed rational discovery assays that, for the first time, enabled the identification and development of novel glue degraders at scale, putting them at theforefront of charting this unexplored chemical space. | Grant / Jul 31, 2020 | ||
| MabVax is a clinical stage biopharmaceutical company focused on the commercialization of proprietary anti-cancer immunotherapies resulting from two integrated and successful technology platforms. The first is a series of vaccines developed at Memorial Sloan-Kettering Cancer Center (MSKCC) and licensed to MabVax. Two of the company’s lead cancervaccines are currently undergoing proof of concept Phase II multi-center clinical trials for the treatment of soft tissue sarcoma and ovarian cancer. Both trials have received $2MM or more in federal grant monies. The second is a human antibody discovery platform developed internally and based on the protective immune responses generated from patients who have been successfully immunized against targeted cancers with the licensed vaccines. The company’s lead human antibody candidate is undergoing preclinical evaluation for development against colon, pancreatic and breast cancers and has received $1.1MM in federal grant monies. | $11M / Post-IPO Equity / Jul 09, 2018 | ||
| Greybox Solution is a digital turbo-charged healthcare platform. | Series A / Jan 01, 2018 | ||
| Promethera® Biosciences is a biopharmaceutical company, spin-off of the Université Catholique de Louvain, that develops innovative treatments based on allogeneic adult stem cell technology.Promethera® Biosciences' mission is to discover, develop and commercialize cell therapy products to treat liver diseases in an innovative way usingallogenic progenitor cells from healthy human livers.Promethera® Biosciences develops two products based on a newly discovered and patented progenitor cell type: the human Adult Liver-Derived Mesenchymal Progenitor Cell (hALDMSC): | $27.8M / Series C / Nov 25, 2014 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Boehringer Ingelheim invest in?
Boehringer Ingelheim invests primarily in Health Care, Biotechnology and Medical startups, most often at Grant and Series A stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Boehringer Ingelheim?
Public channels for Boehringer Ingelheim include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Boehringer Ingelheim?
The team at Boehringer Ingelheim includes Anjan Chatterjee (Corporate Vice President), Christian Eckermann (SVP, Head of Biopharma Austria) and Ioannis Sapountzis (Global Head BD&L), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
